Table 1.
Characteristics of study cohort (N = 1746)
| Patient/clinical characteristic |
Total (N = 1746) | EGFR (n = 458) | ALK (n = 65) | BRAF (n = 146) | KRAS (n = 1077) | p value |
|---|---|---|---|---|---|---|
| Sex, n (%) | ||||||
| Male | 730 (41.8) | 163 (35.6) | 33 (50.8) | 68 (46.6) | 466 (43.3) | 0.008 |
| Female | 1016 (58.2) | 295 (64.4) | 32 (49.2) | 78 (53.4) | 611 (56.7) | |
| Age, n (%) | ||||||
| < 65 years | 609 (34.9) | 161 (35.2) | 34 (52.3) | 46 (31.5) | 368 (34.2) | 0.022 |
| ≥ 65 years | 1137 (65.1) | 297 (64.8) | 31 (47.7) | 100 (68.5) | 709 (65.8) | |
| Histology, n (%) | ||||||
| Nonsquamous | 1584 (90.7) | 425 (92.8) | 58 (89.2) | 124 (84.9) | 977 (90.7) | 0.111 |
| Squamous | 115 (6.6) | 24 (5.2) | 6 (9.2) | 17 (11.6) | 68 (6.3) | |
| NSCLC NOS | 47 (2.7) | 9 (2.0) | 1 (1.5) | 5 (3.4) | 32 (3.0) | |
| Checkpoint inhibitor, n (%) | ||||||
| First line | 520 (29.8) | 40 (8.7) | 11 (16.9) | 57 (39.0) | 412 (38.3) | < 0.001 |
| Second line | 751 (43.0) | 161 (35.2) | 19 (29.2) | 73 (50.0) | 498 (46.2) | |
| ≥ Third line | 475 (27.2) | 257 (56.1) | 35 (53.8) | 16 (11.0) | 167 (15.5) | |
| Smoking history, n (%) | ||||||
| Yes | 1412 (80.9) | 240 (52.4) | 29 (44.6) | 126 (86.3) | 1017 (94.4) | < 0.001 |
| No | 334 (19.1) | 218 (47.6) | 36 (55.4) | 20 (13.7) | 60 (5.6) | |
| PD-L1 expression, n (%)* | ||||||
| ≥ 1% | 587 (74.1) | 116 (69.5) | 25 (80.6) | 62 (77.5) | 384 (74.7) | 0.370 |
| < 1% | 205 (25.9) | 51 (30.5) | 6 (19.4) | 18 (22.5) | 130 (25.3) | |
*
A subset of 792 patients had available data on percentage of tumor cells staining for PD-L1